Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Medical countermeasures against henipaviruses: a review and public health perspective.
Gómez Román R, Tornieporth N, Cherian NG, Shurtleff AC, L'Azou Jackson M, Yeskey D, Hacker A, Mungai E, Le TT. Gómez Román R, et al. Among authors: tornieporth n. Lancet Infect Dis. 2022 Jan;22(1):e13-e27. doi: 10.1016/S1473-3099(21)00400-X. Epub 2021 Nov 1. Lancet Infect Dis. 2022. PMID: 34735799 Free PMC article. Review.
A review of Lassa fever vaccine candidates.
Salami K, Gouglas D, Schmaljohn C, Saville M, Tornieporth N. Salami K, et al. Among authors: tornieporth n. Curr Opin Virol. 2019 Aug;37:105-111. doi: 10.1016/j.coviro.2019.07.006. Epub 2019 Aug 28. Curr Opin Virol. 2019. PMID: 31472333 Review.
Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
Voss G, Jacquet JM, Tornieporth N, Kampmann B, Karron R, Meulen AS, Chen R, Gruber M, Lurie N, Weller C, Cramer JP, Saville M, Darko M. Voss G, et al. Among authors: tornieporth n. Vaccine. 2021 Dec 17;39(51):7357-7362. doi: 10.1016/j.vaccine.2021.10.048. Epub 2021 Nov 17. Vaccine. 2021. PMID: 34799142 Free PMC article.
WHO preferred product characteristics for new vaccines against tuberculosis.
Schrager LK, Chandrasekaran P, Fritzell BH, Hatherill M, Lambert PH, McShane H, Tornieporth N, Vekemans J. Schrager LK, et al. Among authors: tornieporth n. Lancet Infect Dis. 2018 Aug;18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3. Lancet Infect Dis. 2018. PMID: 30064668 No abstract available.
Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F; CYD15 Study Group. Villar L, et al. Among authors: tornieporth n. N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3. N Engl J Med. 2015. PMID: 25365753 Free article. Clinical Trial.
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE, Gray Heppner D Jr, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J; RTS,S/TRAP Group. Kester KE, et al. Among authors: tornieporth n. Vaccine. 2014 Nov 20;32(49):6683-91. doi: 10.1016/j.vaccine.2014.06.033. Epub 2014 Jun 18. Vaccine. 2014. PMID: 24950358 Free article. Clinical Trial.
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group. Kester KE, et al. Among authors: tornieporth n. Vaccine. 2007 Jul 20;25(29):5359-66. doi: 10.1016/j.vaccine.2007.05.005. Epub 2007 May 30. Vaccine. 2007. PMID: 17574311 Clinical Trial.
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Sabchareon A, et al. Lancet. 2012 Nov 3;380(9853):1559-67. doi: 10.1016/S0140-6736(12)61428-7. Epub 2012 Sep 11. Lancet. 2012. PMID: 22975340 Clinical Trial.
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A; CYD14 Study Group. Capeding MR, et al. Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10. Lancet. 2014. PMID: 25018116 Clinical Trial.
62 results